Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Redefine Young: CagriSema and cagrilintide for pediatric weight management
MOH_2026-04-12_015756Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CagriSema, cagrilintide and semaglutide in Overweight and obesity (4 arms), sponsored by Novo Nordisk. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on MOH_2026-04-12_015756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-12_015756.